Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome
Craig G. van Horne
Craig G. van HorneBrain Restoration Center and Departments of Neurosurgery, Brain Restoration Center and
Currently, there is no treatment that slows or halts the progression of Parkinson’s disease. Delivery of various neurotrophic factors to restore dopaminergic function has become a focus of study in an effort to fill this unmet need for patients with Parkinson’s disease. Schwann cells provide a readily available source of such factors. This study presents a 12-month evaluation of safety and feasibility, as well as the clinical response, of implanting autologous peripheral nerve grafts into the substantia nigra of patients with Parkinson’s disease at the time of deep brain stimulation (DBS) surgery.
METHODS
Standard DBS surgery targeting the subthalamic nucleus was performed in 8 study participants. After DBS lead implantation, a section of the sural nerve containing Schwann cells was harvested and unilaterally grafted to the substantia nigra. Adverse events were continually monitored. Baseline clinical data were obtained during standard preoperative evaluations. Clinical outcome data were obtained with postoperative clinical evaluations, neuropsychological testing, and MRI at 1 year after surgery.
RESULTS
All 8 participants were implanted with DBS systems and grafts. Adverse event profiles were comparable to those of standard DBS surgery with the exception of 1 superficial infection at the sural nerve harvest site. Three participants also reported numbness in the distribution of the sural nerve distal to the harvest site. Motor scores on Unified Parkinson’s Disease Rating Scale (UPDRS) part III while the participant was off therapy at 12 months improved from baseline (mean ± SD 25.1 ± 15.9 points at 12 months vs 32.5 ± 9.7 points at baseline). An analysis of the lateralized UPDRS scores also showed a greater overall reduction in scores on the side contralateral to the graft.
CONCLUSIONS
Peripheral nerve graft delivery to the substantia nigra at the time of DBS surgery is feasible and safe based on the results of this initial pilot study. Clinical outcome data from this phase I trial suggests that grafting may have some clinical benefit and certainly warrants further study to determine if this is an efficacious and neurorestorative therapy.
Correspondence Craig G. van Horne: University of Kentucky, Lexington, KY.craigvanhorne@uky.edu.
INCLUDE WHEN CITING Published online February 16, 2018; DOI: 10.3171/2017.8.JNS163222.
Disclosures This work was supported by gifts from the Brain Restoration Center, Tom Dupree for Parkinson’s Disease Research, and Pro’s Players Fore Parkinson’s.
Dr. Gerhardt: previously received research support from Medtronic. Dr. Slevin: received educational support grants from Medtronic. Dr. van Horne: received educational support grants from Medtronic.
Arthur-FarrajPJ,LatoucheM,WiltonDK,QuintesS,ChabrolE,BanerjeeA, et al.:c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration.Neuron75:633–647,2012
BarkerRA,BarrettJ,MasonSL,BjörklundA:Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease.Lancet Neurol12:84–91,2013
BartusRT,BaumannTL,BrownL,KruegelBR,OstroveJM,HerzogCD:Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson’s disease.Neurobiol Aging34:35–61,2013
ChungSJ,JeonSR,KimSR,SungYH,LeeMC:Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease.Eur Neurol56:127–132,2006
CombsHL,FolleyBS,BerryDTR,SegerstromSC,HanDY,Anderson-MooneyAJ, et al.:Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson’s disease: a meta-analysis.Neuropsychol Rev25:439–454,2015
CooperDB,LacritzLH,WeinerMF,RosenbergRN,CullumCM:Category fluency in mild cognitive impairment: reduced effect of practice in test-retest conditions.Alzheimer Dis Assoc Disord18:120–122,2004
DuringMJ,KaplittMG,SternMB,EidelbergD:Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.Hum Gene Ther12:1589–1591,2001
EmreM,AarslandD,BrownR,BurnDJ,DuyckaertsC,MizunoY, et al.:Clinical diagnostic criteria for dementia associated with Parkinson’s disease.Mov Disord22:1689–1707,1837, 2007
FunakoshiH,FrisénJ,BarbanyG,TimmuskT,ZachrissonO,VergeVM, et al.:Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve.J Cell Biol123:455–465,1993
GillSS,PatelNK,HottonGR,O’SullivanK,McCarterR,BunnageM, et al.:Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.Nat Med9:589–595,2003
Graff-RadfordJ,FooteKD,RodriguezRL,FernandezHH,HauserRA,SudhyadhomA, et al.:Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia.Arch Neurol63:1181–1184,2006
GuimaraesP,KieburtzK,GoetzCG,ElmJJ,PaleschYY,HuangP, et al.:Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials.Clin Trials2:509–518,2005
HendersonCE,PhillipsHS,PollockRA,DaviesAM,LemeulleC,ArmaniniM, et al.:GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle.Science266:1062–1064,1994
KordowerJH,FiandacaMS,NotterMF,HansenJT,GashDM:NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells.J Neurosurg73:418–428,1990
LitvanI,GoldmanJG,TrösterAI,SchmandBA,WeintraubD,PetersenRC, et al.:Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines.Mov Disord27:349–356,2012
MarekK,InnisR,van DyckC,FussellB,EarlyM,EberlyS, et al.:[123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression.Neurology57:2089–2094,2001
MarksWJJr,BartusRT,SiffertJ,DavisCS,LozanoA,BoulisN, et al.:Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial.Lancet Neurol9:1164–1172,2010
MarksWJJr,OstremJL,VerhagenL,StarrPA,LarsonPS,BakayRA, et al.:Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial.Lancet Neurol7:400–408,2008
MeyerM,MatsuokaI,WetmoreC,OlsonL,ThoenenH:Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA.J Cell Biol119:45–54,1992
MolinuevoJL,ValldeoriolaF,TolosaE,RumiaJ,Valls-SoleJ,RoldanH, et al.:Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease.Arch Neurol57:983–988,2000
OlanowCW,GoetzCG,KordowerJH,StoesslAJ,SossiV,BrinMF, et al.:A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease.Ann Neurol54:403–414,2003
PatelDM,WalkerHC,BrooksR,OmarN,DittyB,GuthrieBL:Adverse events associated with deep brain stimulation for movement disorders: analysis of 510 consecutive cases.Neurosurgery11(Suppl 2):190–199,2015
PourfarM,TangC,LinT,DhawanV,KaplittMG,EidelbergD:Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET.J Neurosurg110:1278–1282,2009
RowlandNC,KaliaSK,KaliaLV,LarsonPS,LimDA,BankiewiczKS:Merging DBS with viral vector or stem cell implantation: “hybrid” stereotactic surgery as an evolution in the surgical treatment of Parkinson’s disease.Mol Ther Methods Clin Dev3:15051,2016
RowlandNC,StarrPA,LarsonPS,OstremJL,MarksWJJr,LimDA:Combining cell transplants or gene therapy with deep brain stimulation for Parkinson’s disease.Mov Disord30:190–195,2015
ShulmanLM,Gruber-BaldiniAL,AndersonKE,FishmanPS,ReichSG,WeinerWJ:The clinically important difference on the unified Parkinson’s disease rating scale.Arch Neurol67:64–70,2010
SlevinJT,GerhardtGA,SmithCD,GashDM,KryscioR,YoungB:Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.J Neurosurg102:216–222,2005
TemperliP,GhikaJ,VillemureJG,BurkhardPR,BogousslavskyJ,VingerhoetsFJ:How do parkinsonian signs return after discontinuation of subthalamic DBS?Neurology60:78–81,2003
van HorneCG,QuinteroJE,GurwellJA,WagnerRP,SlevinJT,GerhardtGA:Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson’s disease treated with bilateral STN DBS: a report of safety and feasibility.J Neurosurg126:1140–1147,2017
van HorneCG,VaughanSW,MassariC,BennettM,AsfahaniWS,QuinteroJE, et al.:Streamlining deep brain stimulation surgery by reversing the staging order.J Neurosurg122:1042–1047,2015
VenutoCS,PotterNB,DorseyER,KieburtzK:A review of disease progression models of Parkinson’s disease and applications in clinical trials.Mov Disord31:947–956,2016
WalkerHC,WattsRL,GuthrieS,WangD,GuthrieBL:Bilateral effects of unilateral subthalamic deep brain stimulation on Parkinson’s disease at 1 year.Neurosurgery65:302–310,2009
WilliamsNR,FooteKD,OkunMS:STN vs. GPi deep brain stimulation: translating the rematch into clinical practice.Mov Disord Clin Pract (Hoboken)1:24–35,2014
